Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Save

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.

Limited Efficacy of Muscle Relaxants for Chronic Pain

Save

A systematic review of long-term muscle relaxant use for chronic pain suggests they may be effective in treating trigeminal neuralgia, cramps, and neck pain, but not fibromyalgia, low back pain, and other pain syndromes.

I Can't Treat Ugly (9.20.2024)

Save

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Mycophenolate in New-Onset SLE

Save

How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement?

TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients

Save

Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.

Antidepressants for Pain are Weakly Effective

Save

University of Sydney research has found people over 65 are being prescribed antidepressants as pain treatment based on international guidelines that use limited evidence. The study found that in the last 40 years there have been only 15 trials globally focusing on the benefit of antidepressants for pain in older people. This study fills a much-needed gap in research by bringing together the information from these trials to look at the efficacy and harms of antidepressants for acute and chronic non-cancer pain in those over 65 years old.

FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis

Save

Increased Cardiovascular Events in Lupus

Save

A New York surveillance registry (Manhattan Lupus Surveillance Program) estimates higher rates of cardiovascular events (CVE) among systemic lupus erythematosus (SLE) patients, especially amongst younger males, Hispanic/Latinos and non-Hispanic Black patients.

BSR Guidelines for Systemic Sclerosis Management

Save

The British Society for Rheumatology (BSR) has updated its 2015 guidelines for the management of patients with sytemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion. 

Different Autoantibody Phenotypes in Juvenile and Adult Myositis

Save

A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.

Systemic Sclerosis Insights (9.13.2024)

Save

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Increasing Incidence of Morphea

Save

A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.